Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hepatitis E patients

BACKGROUND AND AIMS: Chronic HEV infections remain a serious problem in immunocompromised patients, as specifically approved antiviral drugs are unavailable. In 2020, a 24-week multicenter phase II pilot trial was carried out, evaluating the nucleotide analog sofosbuvir by treating nine chronically...

Descripción completa

Detalles Bibliográficos
Autores principales: Gömer, André, Klöhn, Mara, Jagst, Michelle, Nocke, Maximilian K., Pischke, Sven, Horvatits, Thomas, Schulze zur Wiesch, Julian, Müller, Tobias, Hardtke, Svenja, Cornberg, Markus, Wedemeyer, Heiner, Behrendt, Patrick, Steinmann, Eike, Todt, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Articles: Viral Hepatitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653298/
https://www.ncbi.nlm.nih.gov/pubmed/37334496
http://dx.doi.org/10.1097/HEP.0000000000000514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653298/
https://www.ncbi.nlm.nih.gov/pubmed/37334496
http://dx.doi.org/10.1097/HEP.0000000000000514

Ejemplares similares